Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications

Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications

Around 80–90% of prostate cancer (PCa) cases are dependent on androgens at initial diagnosis; hence, androgen ablation therapy directed toward a reduction in serum androgens and the inhibition of androgen receptor (AR) is generally the first therapy adopted. However, the patient’s response to androg...

Full description

Bibliographic Details
Main Authors: Gaetano Aurilio, Alessia Cimadamore, Roberta Mazzucchelli, Antonio Lopez-Beltran, Elena Verri, Marina Scarpelli, Francesco Massari, Liang Cheng, Matteo Santoni, Rodolfo Montironi
Format: Article
Language:English
Published: MDPI AG 2020-12-01
Series:Cells
Subjects:
prostate cancer
androgen receptor
AR-V7
AR variants
AR antagonists
AR resistance
Online Access:https://www.mdpi.com/2073-4409/9/12/2653

Internet

https://www.mdpi.com/2073-4409/9/12/2653

Similar Items